特应性皮炎治疗药物研究进展

doi:10.3760/cma.j.issn.0412-4030.2019.01.019

中华皮肤科杂志 ›› 2019, Vol. 52 ›› Issue (1): 57-60.doi: 10.3760/cma.j.issn.0412-4030.2019.01.019

特应性皮炎治疗药物研究进展

胡宇晴张建中

北京大学人民医院皮肤科，100044

收稿日期:2018-01-18 修回日期:2018-05-28 发布日期:2019-01-02
通讯作者: 张建中 E-mail:rmzjz@126.com

Medications for atopic dermatitis

Hu Yuqing, Zhang Jianzhong

Department of Dermatology, Peking University People′s Hospital, Beijing 100044, China

Received:2018-01-18 Revised:2018-05-28 Published:2019-01-02
Contact: Zhang Jianzhong E-mail:rmzjz@126.com

摘要/Abstract

摘要： 【摘要】特应性皮炎的发病机制尚未完全清楚，可能与免疫紊乱、皮肤屏障功能障碍及环境因素有关。特应性皮炎最重要的症状是严重瘙痒，并可极大地影响患者的生活质量。目前其治疗仍然是一个挑战。多数患者可通过避免激发因素、基础皮肤护理和外用抗炎药得到较好疗效；少部分患者皮损广泛且对常规治疗抵抗，需要系统治疗。生物制剂在中重度特应性皮炎患者中已得到较广泛地应用。本文综述特应性皮炎的药物治疗研究进展。

关键词: 皮炎, 特应性；治疗, 临床研究性；生物疗法

Abstract: 【Abstract】 The pathogenesis of atopic dermatitis （AD） has not been fully elucidated, which may be mainly associated with abnormality of immunity, dysfunction of skin barrier and environmental factors. The main symptom of AD is severe pruritus, which can greatly affect the life quality of patients. The management of AD in clinical practice is still a big challenge. Most patients can achieve improvement through avoidance of provocative factors, basic skin care and topical application of anti-inflammatory agents. However, a few patients with generalized lesions are resistant to conventional therapy, and systemic therapy is needed. Biological agents have been widely used in patients with moderate and severe AD. This review summarizes advances in the medications for AD.

Key words: Dermatitis, atopic, Therapies, investigational, Biological therapy

中图分类号:

胡宇晴张建中. 特应性皮炎治疗药物研究进展[J]. 中华皮肤科杂志, 2019,52(1):57-60. doi:10.3760/cma.j.issn.0412-4030.2019.01.019

Hu Yuqing, Zhang Jianzhong. Medications for atopic dermatitis[J]. Chinese Journal of Dermatology, 2019, 52(1): 57-60.doi:10.3760/cma.j.issn.0412-4030.2019.01.019

参考文献 24

［1］	Osinka K, Dumycz K, Kwiek B, et al. Novel therapeutic approaches to atopic dermatitis［J］. Arch Immunol Ther Exp （Warsz）, 2018,66（3）:171⁃181. doi: 10.1007/s00005⁃017⁃0487⁃1.
［2］	Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in chinese children aged 1⁃7 ys［J］. Sci Rep, 2016,6:29751. doi: 10.1038/srep29751.
［3］	Pyun BY. Natural history and risk factors of atopic dermatitis in children［J］. Allergy Asthma Immunol Res, 2015,7（2）:101⁃105. doi: 10.4168/aair.2015.7.2.101.
［4］	Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014,70（2）:338⁃351. doi: 10.1016/j.jaad.2013.10.010.
［5］	Shainhouse T, Eichenfield LF. Long⁃term safety of tacrolimus ointment in children treated for atopic dermatitis［J］. Expert Opin Drug Saf, 2003,2（5）:457⁃465. doi: 10.1517/14740338.2.5. 457.
［6］	Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report［J］. J Allergy Clin Immunol, 2006,118（1）:152⁃169. doi: 10.1016/ j.jaci.2006.03.045.
［7］	Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights［J］. J Allergy Clin Immunol, 2008,122（6）:1074⁃1081. doi: 10.1016/j.jaci.2008.09.042.
［8］	Ibler KS, Jemec GB. Novel investigational therapies for atopic dermatitis［J］. Expert Opin Investig Drugs, 2015,24（1）:61⁃68. doi: 10.1517/13543784.2015.957756.
［9］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［10］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［11］	Oldhoff JM, Darsow U, Werfel T, et al. Anti⁃IL⁃5 recombinant humanized monoclonal antibody （mepolizumab） for the treatment of atopic dermatitis［J］. Allergy, 2005,60（5）:693⁃696. doi: 10. 1111/j.1398⁃9995.2005.00791.x.
［12］	Ruzicka T, Hanifin JM, Furue M, et al. Anti⁃interleukin⁃31 receptor a antibody for atopic dermatitis［J］. N Engl J Med, 2017,376（9）:826⁃835. doi: 10.1056/NEJMoa1606490.
［13］	Fernández⁃Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, et al. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients［J］. Actas Dermosifiliogr, 2014,105（3）:312⁃313. doi: 10.1016/j.adengl.2013.05.005.
［14］	Sedivá A, Kayserová J, Vernerová E, et al. Anti⁃CD20 （rituximab） treatment for atopic eczema［J］. J Allergy Clin Immunol, 2008,121（6）:1515⁃1517. doi: 10.1016/j.jaci.2008.03.007.
［15］	McDonald BS, Jones J, Rustin M. Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients［J］. Clin Exp Dermatol, 2016,41（1）:45⁃47. doi: 10.1111/ ced.12691.
［16］	Fernández⁃Antón Martínez MC, Leis⁃Dosil V, Alfageme⁃Roldán F, et al. Omalizumab for the treatment of atopic dermatitis［J］. Actas Dermosifiliogr, 2012,103（7）:624⁃628. doi: 10.1016/j.ad. 2011.07.013.
［17］	Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis［J］. J Am Acad Dermatol, 2005,52（3 Pt 1）:522⁃526. doi: 10.1016/j.jaad.2004.11.022.
［18］	Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2 in patients Ages 2 to 17 years with atopic dermatitis: a phase 1b, open⁃label, maximal⁃use systemic exposure study［J］. Pediatr Dermatol, 2016,33（4）:380⁃387. doi: 10.1111/pde.12872.
［19］	Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503. doi: 10.1016/j.jaad.2016.05.046.
［20］	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.
［21］	Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought?［J］. J Allergy Clin Immunol, 2017,140（3）:633⁃643. doi: 10.1016/j.jaci.2017.07.006.
［22］	Zhao L, Chen X, Cai L, et al. Randomized, double⁃blind, placebo⁃controlled, multiple⁃dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis［J］. J Clin Pharm Ther, 2014,39（4）:418⁃423. doi: 10.1111/jcpt.12158.
［23］	Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI⁃1001 in patients with mild to severe atopic dermatitis: results from a 12⁃week, multicentre, randomized, placebo⁃controlled double⁃blind trial［J］. Br J Dermatol, 2012,166（4）:853⁃860. doi: 10.1111/j.1365⁃2133.2011.10775.x.
［24］	Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention［J］. J Allergy Clin Immunol, 2014,134（4）:818⁃823. doi: 10.1016/j.jaci.2014.08.005.

[1]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[2]	郭昊刘辉张丽朱冠男王平姚志荣高兴华陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814.
[3]	陈春里闫思聿王丹高丽华谭丽娜唐四元刘伟曾金容鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831.
[4]	王珊王星宇舒虹张斌石航杨欢钱秋芳马红艳梁源赵牧童申春平焦磊田晶汪洋谷盈孙婧刘盈李萍王华马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821.
[5]	申春平李萍罗晓燕梁源刘盈赵牧童王珊田晶焦磊汪洋罗珍余时娟方晓王华马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762.
[6]	徐西利李东宁段函王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750.
[7]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[8]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[9]	渠莉田陈锦丛程波苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656.
[10]	蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692.
[11]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[12]	李嘉祺叶枫鞠强. 表皮葡萄球菌共生性稳态与皮肤疾病[J]. 中华皮肤科杂志, 2023, 56(5): 459-462.
[13]	周园姚煦. 微生物群体感应系统在皮肤炎症发展中的作用机制[J]. 中华皮肤科杂志, 2023, 56(4): 372-375.
[14]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中国老年保健医学研究会皮肤科分会中国中药协会皮肤病药物研究专业委员会. [开放获取] 湿疹皮炎类皮肤病中西医结合药物治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(4): 287-293.
[15]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 56(4): 325-329.

特应性皮炎治疗药物研究进展

Medications for atopic dermatitis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

Metrics

本文评价

推荐阅读 10